WO2003014728A1 - Remedies for hepatitis c - Google Patents

Remedies for hepatitis c Download PDF

Info

Publication number
WO2003014728A1
WO2003014728A1 PCT/JP2002/008175 JP0208175W WO03014728A1 WO 2003014728 A1 WO2003014728 A1 WO 2003014728A1 JP 0208175 W JP0208175 W JP 0208175W WO 03014728 A1 WO03014728 A1 WO 03014728A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
protein
virus
antibody
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008175
Other languages
French (fr)
Japanese (ja)
Inventor
Seima Itami
Makoto Seki
Masahiro Kito
Yoshiharu Matsuura
Tatsuo Miyamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
National Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, National Institute of Infectious Diseases filed Critical Mitsubishi Pharma Corp
Priority to JP2003519409A priority Critical patent/JP4221292B2/en
Publication of WO2003014728A1 publication Critical patent/WO2003014728A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of screening a substance inhibiting the binding of hepatitis C virus E2/NS1 protein to an antibody having an affinity for the protein, which involves: (1) the step of bringing the hepatitis C virus E2/NS1 protein into contact with the above-described antibody in the presence and absence of a test substance; and (2) the step of comparing the binding of the hepatitis C virus E2/NS1 protein to the antibody in the presence and absence of a test substance. Thus, it becomes possible to provide novel drugs having antiviral effects of, for example, preventing infection with HCV.
PCT/JP2002/008175 2001-08-10 2002-08-09 Remedies for hepatitis c Ceased WO2003014728A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003519409A JP4221292B2 (en) 2001-08-10 2002-08-09 Hepatitis C drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001243947 2001-08-10
JP2001-243947 2001-08-10

Publications (1)

Publication Number Publication Date
WO2003014728A1 true WO2003014728A1 (en) 2003-02-20

Family

ID=19073953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008175 Ceased WO2003014728A1 (en) 2001-08-10 2002-08-09 Remedies for hepatitis c

Country Status (2)

Country Link
JP (1) JP4221292B2 (en)
WO (1) WO2003014728A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057339A1 (en) * 2004-11-25 2006-06-01 Mitsubishi Pharma Corporation Method of producing antibody
EP4158034A4 (en) * 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018198A1 (en) * 1997-10-06 1999-04-15 Chiron S.P.A. Hepatitis c receptor protein cd81

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018198A1 (en) * 1997-10-06 1999-04-15 Chiron S.P.A. Hepatitis c receptor protein cd81

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLANDER TOBIAS ET AL.: "Recombinant human monoclobal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", vol. 81, no. 10, October 2000 (2000-10-01), pages 2451 - 2459, XP002939743 *
PILERI P. ET AL.: "Binding of hepatitic C virus to CD81", SCIENCE, vol. 282, 30 October 1998 (1998-10-30), pages 938 - 941, XP002092549 *
SHU KIKUCHI ET AL.: "Ketsueki baikai kansensho HCV", RINSHO TO KENKYU, vol. 76, no. 7, 1999, pages 1260 - 1266, XP002961752 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057339A1 (en) * 2004-11-25 2006-06-01 Mitsubishi Pharma Corporation Method of producing antibody
EP4158034A4 (en) * 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS

Also Published As

Publication number Publication date
JP4221292B2 (en) 2009-02-12
JPWO2003014728A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
ID21649A (en) INHIBITOR SERUM PROTEASE, ESPECIALLY VIRUS HEPATITIS C NS3 PROTEASE
DK0458841T3 (en) Process for use and preparation of peptides
HK1049184A1 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
GB2365429B (en) Improvements to ribosome display
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2003002749A3 (en) Methods for the simultaneous detection of hcv antigens and hcv antibodies
PT698216E (en) HEPATITIS C VIRUS TYPES OF METHODS AND REAGENTS FOR USE IN THESE
AU2001232267A1 (en) Remedies for hepatitis c
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
HK1049185A1 (en) Modified fluorescent proteins
WO2002062959A3 (en) Hepatitis b virus treatment
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO1996035717A3 (en) Soluble, cleavable substrates of the hepatitis c virus protease
WO2003014728A1 (en) Remedies for hepatitis c
WO2002055560A3 (en) Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
ATE472337T1 (en) PHARMACEUTICAL COMPOSITION OF F(AB) 2 FRAGMENTS OF ANTIBODIES AND METHOD FOR THE PRODUCTION THEREOF
WO2004014936A3 (en) Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
EP0516859A4 (en)
AU8405798A (en) A swine hepatitis e virus and uses thereof
WO2002100900A3 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
WO1998018818A3 (en) Hepatitis b inhibitors
WO2001092321A3 (en) Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes
WO2002088740A3 (en) Method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003519409

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase